RC
BIO icon

RegentAtlantic Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

RegentAtlantic Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$834K Sell
1,999
-107
-5% -$53.3K 0.02% 347
2022
Q2 		$1.04M Sell
2,106
-47
-2% -$24.5K 0.03% 307
2022
Q1 		$1.21M Sell
2,153
-63
-3% -$38K 0.03% 285
2021
Q4 		$1.67M Sell
2,216
-72
-3% -$53.9K 0.05% 245
2021
Q3 		$1.71M Sell
2,288
-204
-8% -$153K 0.05% 226
2021
Q2 		$1.61M Sell
2,492
-110
-4% -$66.9K 0.05% 232
2021
Q1 		$1.49M Sell
2,602
-213
-8% -$126K 0.05% 225
2020
Q4 		$2K Sell
2,815
-52
-2% -$29.6K ﹤0.01% 503
2020
Q3 		$1.48M Buy
2,867
+26
+0.9% +$13.2K 0.07% 185
2020
Q2 		$1.28M Buy
2,841
+223
+9% +$98.4K 0.07% 194
2020
Q1 		$918K Buy
2,618
+317
+14% +$117K 0.07% 212
2019
Q4 		$851K Buy
2,301
+408
+22% +$144K 0.05% 255
2019
Q3 		$630K Sell
1,893
-77
-4% -$25.1K 0.04% 273
2019
Q2 		$616K Sell
1,970
-33
-2% -$9.88K 0.04% 273
2019
Q1 		$612K Buy
2,003
+12
+0.6% +$3.24K 0.04% 267
2018
Q4 		$462K Buy
1,991
+1,283
+181% +$344K 0.04% 291
2018
Q3 		$222K Buy
+708
New +$220K 0.02% 409
2015
Q1 		– Sell
-238
Closed -$28.7K – 418
2014
Q4 		$28.7K Buy
+238
New +$27.4K ﹤0.01% 687

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RegentAtlantic Capital's BIO Position: Q3 2022 in Review

RegentAtlantic Capital reduced its Bio-Rad Laboratories Class A (BIO) stake by 5.1% in Q3 2022, selling an estimated $53.3K and leaving 1,999 shares worth $834K. The position accounts for 0.02% of the portfolio, ranked #347.

RegentAtlantic Capital first reported a position in BIO in Q4 2014 and has held it in 18 quarters since. The position peaked at $1.71M in Q3 2021. 485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • RegentAtlantic Capital held 1,999 shares of Bio-Rad Laboratories Class A worth $834K as of Q3 2022.
  • RegentAtlantic Capital sold 107 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $53.3K.
  • Bio-Rad Laboratories Class A made up 0.02% of RegentAtlantic Capital's portfolio in Q3 2022, its #347 holding.
  • RegentAtlantic Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2014 and has held it in 18 quarters since.
  • RegentAtlantic Capital's Bio-Rad Laboratories Class A position peaked at $1.71M in Q3 2021.
  • 485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.